What were Jefferies' key financial highlights for the second quarter ended May 31, 2026?

Jefferies reported profit attributable to common shareholders of $226.2 million, or $1.02 per share, more than double the $88 million, or 40 cents per share, from the same period a year earlier; advisory revenue surged 47% to a record $674.1 million; investment banking net revenues jumped 57.5% year-over-year to a record $1.21 billion; equity underwriting revenue more than tripled to $370.7 million; and capital markets revenue rose 13.5% to $799.3 million, with equities trading up 14% to a record $600.8 million.

Which major deals did Jefferies advise on during the quarter, and what sectors drove global M&A activity?

Jefferies advised Sun Pharmaceutical on its $11.75 billion acquisition of Organon and Kelonia Therapeutics on its sale to Eli Lilly for up to $7 billion; globally, M&A volumes exceeded $2.8 trillion in 2026, driven by the technology, healthcare, and utility and energy sectors.

Jefferies Quarterly Profit More Than Doubles on Dealmaking, Equities Strength

Jun 24, 2026

Jefferies reported Q2 profit doubling driven by M&A advisory fees, including advising on Sun Pharma's $11.75B acquisition of Organon and Kelonia's sale to Eli Lilly.

reuters

2026-06-24

Jefferies Quarterly Profit More Than Doubles on Dealmaking, Equities Strength

FAQ

Scan to get the App